MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Aadi Bioscience, Inc. (NASDAQ: AADI)
Organization & Developments: Aadi Bioscience
Parents
Aadi Bioscience, Inc. (NASDAQ: AADI)
Children
*Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.
*Aadi’s lead product is FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension
*Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.
*ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models2.
*Nab-sirolimus
2021: Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement -
2022: Aadi Bioscience (AADI) Investor Presentation - Slideshow_seekingalpha.com
2022: Aadi Bioscience (AADI) Presents At Ladenburg Thalmann Healthcare Conference - Slideshow_ seekingalpha.com
2022: Aadi Bioscience: Taking mTOR Inhibition To The Next Level_ seekingalpha.com
2024: Aadi Bioscience to Lay Off 80% of R&D Staff
Jumps
Finance & Acquisitions: Aadi Bioscience
Key People: Aadi Bioscience